November 18, 2022
Jazz Pharmaceuticals has two weeks to ask the U.S. Food and Drug Administration to pull a patent that purportedly covers a narcolepsy drug from the agency's so-called Orange Book after a Delaware federal court found that it covers a distribution method and not the drug itself.
November 14, 2022
The Federal Trade Commission urged a Delaware federal court to remove a patent for narcolepsy drug distribution from federal regulators' list of approved drugs and the patents covering them, arguing the patent was improperly included and is blocking competition.